Wall Street Zen downgraded shares of uniQure (NASDAQ:QURE – Free Report) from a hold rating to a sell rating in a research note released on Saturday. Based on data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus price target of $65.00. Get uniQure alerts:View Our Latest Stock Analysis on QUREuniQure Stock Up 1.0%Shares of QURE stock opened at $44.06 on Friday. Following the completion of the transaction, the insider owned 169,669 shares of the company’s stock, valued at approximately $4,251,905.14. uniQure Company Profile(Get Free Report)uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs.